| 摘要 |
A therapeutic agent of allergic airway disease and airway remodeling comprising wortmannin as a PI3K(phosphoinositide 3-kinases) inhibitor is provided to inhibit increased blood permeability and following inflammation responses and airway hypersensitiveness by suppressing VEGF(vascular endothelial growth factor). A 50-100mug of wortmannin as a PI3K(phosphoinositide 3-kinases) inhibitor is administered into the airway in 1-3 times at an interval of 48 hours to inhibit airway remodeling or VEGF, reduce vascular permeability or improve airway hypersensitiveness or airway inflammation in allergic airway disease. A therapeutic agent of allergic airway disease and airway remodeling comprises wortmannin as an effective ingredient.
|
